文献速递肾移植慢性肾脏病遗传性与小管间质肾病

儿童慢性移植肾肾病中盐皮质激素受体阻断的随机对照试验

Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-05-23

虽然研究效力不足,但依普利酮组在肾小球滤过率、小管间质纤维化、肾小球硬化及尿HSP72方面表现出优于安慰剂的趋势,鼓励在该儿童人群中进一步测试MRB的潜在获益。

要点

  • 儿童慢性移植肾肾病患者使用依普利酮25 mg/d治疗24个月耐受性良好。
  • 依普利酮组24个月时eGFR数值高于安慰剂组,但差异无统计学意义。
  • 依普利酮组小管间质纤维化、肾小球硬化和尿HSP72低于安慰剂组。

核心结论

  • 研究效力不足,无法提供长期依普利酮延缓儿童CAN进展的确定性证据,但鼓励进一步测试MRB的潜在获益。

主要发现

  • 基线eGFR在安慰剂组为80±6、依普利酮组为86±6 ml/min per 1.73 m2,24个月时分别为66±8和81±7 ml/min per 1.73 m2(P=0.33;95%CI基线-18至33,24个月-11至40)。
  • 尿白蛋白/肌酐比值在安慰剂组基线为110±74、依普利酮组为265±140 mg/g,24个月时分别为276±140和228±88 mg/g(P=0.15;95%CI分别为-283至593和-485至391)。
  • 安慰剂组小管间质纤维化、肾小球硬化和尿HSP72高于依普利酮组。

临床怎么用

  • 对于活检证实的儿童慢性移植肾肾病,可考虑在密切监测下试用依普利酮25 mg/d,但当前证据尚不足以支持常规推荐。

局限性

  • 研究效力不足(样本量小),无法得出确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: We showed that mineralocorticoid receptor blockade (MRB) prevented acute and chronic cyclosporine nephropathy (CsA-Nx) in the rat. The aim of this translational study was to investigate the effect of long-term eplerenone administration on renal allograft function in children with biopsy-proven chronic allograft nephropathy (CAN). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Renal transplant children <18 years, biopsy-proven CAN, and a GFR>40 ml/min per 1.73 m2 were included. Patients with BK virus active nephritis, recurrence of renal disease, GFR decline in previous 3 months, or treated with calcium antagonists or antifungal drugs were excluded. They were randomized to receive placebo (n=10) or eplerenone 25 mg/d for 24 months (n=13). Visits were scheduled at baseline, 6, 12, and 24 months. At each period, a complete clinical examination was performed and blood and urine samples were taken. Urine creatinine, 8-hydroxylated-guanosine, heat shock protein 72 (HSP72), and kidney injury molecule (KIM-1) levels were also assessed. In kidney biopsy samples, the tubulo-interstitial area affected by fibrosis (TIF) and glomerulosclerosis were measured at baseline and after 24 months. RESULTS: The baseline eGFR was 80±6 in the placebo and 86±6 ml/min per 1.73 m2 in the eplerenone group; at 24 months it was 66±8 and 81±7 ml/min per 1.73 m2, respectively (P=0.33; 95% confidence intervals, -18 to 33 at baseline, and -11 to 40 after 24 months). The albumin-to-creatinine ratio was 110±74 in the placebo, and 265±140 mg/g in the eplerenone group; and after 24 months it was 276±140 and 228±88 mg/g, respectively (P=0.15; 95% confidence intervals, -283 to 593, and -485 to 391, respectively). In addition, the placebo exhibited a greater TIF, glomerulosclerosis, and urinary HSP72 compared with the eplerenone group. CONCLUSIONS: Although this study was underpowered to provide definitive evidence that long-term eplerenone administration attenuates the progression of CAN in pediatric transplant patients, it encourages testing the potential benefit of MRB in this pediatric population.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Medeiros M, Velásquez-Jones L, Hernández AM, et al. Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy. Clin J Am Soc Nephrol. 2017. PMID: 28536123. doi:10.2215/CJN.05300516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。